Datopotamab deruxtecan

Lung cancer is a leading cause of cancer death globally, with NSCLC being the most common type. LAURA is a Phase III trial testing Tagrisso, a third-generation EGFR-TKI, in Stage III EGFRm NSCLC patients. Tagrisso has shown efficacy in various stages of NSCLC and is part of AstraZeneca's comprehensive lung cancer portfolio. The company aims to redefine cancer care and eliminate it as a cause of death.

FDA receives BLA for Dato-DXd in EGFR+ advanced NSCLC; RP1 plus nivolumab shows activity in advanced melanoma post-PD-1 therapy; 177Lu-PSMA-I&T meets rPFS endpoint in PSMA+ mCRPC; refined platinum resistance definition and novel ADCs impact ovarian cancer treatment; CHMP recommends isatuximab plus VRd for transplant-ineligible myeloma; CHMP also supports repotrectinib, pembrolizumab plus chemo, nivolumab plus ipilimumab, and denosumab biosimilars.

A new BLA for Dato-DXd in EGFR-mutated NSCLC was submitted, replacing the earlier nonsquamous NSCLC application, based on phase 2 and 3 trial data. This decision followed FDA feedback and aims for accelerated approval.

Syros Pharmaceuticals' phase III study for tamibarotene in MDS missed primary endpoint; Amgen's stock steady despite analyst report; Adaptimmune reports positive results for lete-cel; Daiichi Sankyo and Astrazeneca submit new BLA for lung cancer treatment; Apollo Therapeutics signs $938 million deal with Sunshine Lake Pharma; study identifies quiescent cancer stem cells in glioblastoma relapse; Modifi Biosciences acquired by Merck for up to $1.3 billion.

AstraZeneca and Daiichi Sankyo submitted a new BLA to the FDA seeking accelerated approval for datopotamab deruxtecan (Dato-DXd) to treat EGFR-mutated NSCLC, based on Phase II TROPION-Lung05 trial results. The decision follows FDA feedback and withdrawal of a previous BLA. The therapy, a TROP2-directed ADC, aims to improve outcomes for advanced lung cancer patients.

At the 2024 WCLC, 7,000+ clinicians and scientists gathered to review impactful abstracts on lung cancer treatments, including novel perioperative strategies for resectable lung cancer and the use of tyrosine kinase inhibitors, bispecific antibodies, and ADCs in advanced NSCLC and SCLC. Key findings included superior event-free survival with perioperative nivolumab, high pathologic response rates with ADCs in localized NSCLC, and promising outcomes with EGFR-MET bispecific antibodies and HER2-targeted therapies. The conference also highlighted the potential of ADCs in SCLC and the need for improved biomarker development and patient selection tools.

AstraZeneca and Daiichi Sankyo submitted a new BLA for datopotamab deruxtecan for EGFR-mutated NSCLC, withdrawing a previous BLA for nonsquamous NSCLC. The decision was based on FDA feedback and trial data showing pronounced benefits for EGFR-mutated patients.

AstraZeneca and Daiichi Sankyo submitted a BLA to the FDA for accelerated approval of datopotamab deruxtecan (Dato-DXd) in previously treated, advanced EGFR-mutated NSCLC, based on TROPION-Lung05 Phase II trial results. The companies withdrew a previous BLA for Dato-DXd in advanced or metastatic nonsquamous NSCLC.

The FDA received a new BLA for datopotamab deruxtecan (Dato-DXd) for advanced NSCLC with EGFR mutations, supported by phase 2 TROPION-Lung05 data showing 43.6% ORR and 82.1% DCR. AstraZeneca and Daiichi Sankyo withdrew the BLA for nonsquamous NSCLC, previously accepted in February 2024. TROPION-Lung01 data showed Dato-DXd's potential benefit, especially for EGFR-mutated patients, informing the new BLA submission.

AstraZeneca and Daiichi Sankyo submitted a new BLA for datopotamab deruxtecan (Dato-DXd) for EGFR-mutated NSCLC, withdrawing a previous BLA for nonsquamous NSCLC based on FDA feedback. The new BLA is supported by TROPION-Lung05 Phase II trial data and will be presented at ESMO Asia 2024.